Format

Send to

Choose Destination
Asia Pac J Ophthalmol (Phila). 2019 Jan-Feb;8(1):62-72. doi: 10.22608/APO.2018182. Epub 2018 Nov 2.

Neurofibromatosis Type 1: Review and Update on Emerging Therapies.

Author information

1
Discipline of Ophthalmology, Save Sight Institute, Sydney Medical School, University of Sydney, Sydney, Australia.
2
Manchester Royal Eye Hospital, Manchester, United Kingdom.
3
Royal Darwin Hospital, Darwin, Australia.
4
Disciplines of Paediatrics, Genomic Medicine and Ophthalmology, Sydney Medical School, University of Sydney, Sydney, Australia.
5
Eye Genetics Research Unit, Children's Medical Research Institute, University of Sydney, Sydney, Australia.
6
Save Sight Institute and Eye Genetics Clinics, The Children's Hospital at Westmead, Sydney, Australia.
7
Westmead Hospital, Sydney, Australia.
8
Department of Ophthalmology, The Children's Hospital at Westmead, Sydney, Australia.
9
Sydney Eye Hospital, Sydney, Australia.

Abstract

Neurofibromatosis type 1 is an autosomal dominant neurocutaneous disorder affecting 1 in 3000 births. This familial tumor predisposition syndrome is diagnosed clinically and affects the skin, bones, and nervous system. Malignant tumors can arise in childhood or adulthood and are the most common cause of mortality in this population. Early diagnosis and management led by a multidisciplinary team remains the standard of care, particularly in the management of optic pathway glioma. Emerging concepts in the genetic patterns of this condition have led to the introduction of new treatment modalities that target the mitogen-activated protein kinase and the mammalian target of rapamycin pathways. In this review, the role of the ophthalmologist and approach to screening for optic pathway glioma are outlined based on previous recommendations. Updates on choroidal involvement, as a diagnostic criterion, will also be discussed, further highlighting the pivotal role of the ophthalmologist in the diagnosis and management of this complex condition.

KEYWORDS:

choroidal nodules; neurofibromatosis 1; optic pathway glioma; phakomatoses

PMID:
30387339
DOI:
10.22608/APO.2018182
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center